This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Articles

Randomized, Double-Blind, Placebo-Controlled Study of Divalproex Extended Release Loading Monotherapy in Ambulatory Bipolar Spectrum Disorder Patients With Moderate-to-Severe Hypomania or Mild Mania

Susan L. McElroy, MD; Brian E. Martens, LSW, MS; Ryan S. Creech, BA; Jeffrey A. Welge, PhD; Lena Jefferson, MD; Anna I. Guerdjikova, PhD, LISW; and Paul E. Keck Jr, MD

Published: February 23, 2010

Article Abstract

Objective: To determine whether divalproex extended release (ER) would be effective in outpatients with DSM-IV-TR-diagnosed ambulatory bipolar spectrum disorder (BSD) and moderate-to-severe hypomanic or mild manic symptoms (hypomania/mild mania).

Method: An 8-week, randomized, double-blind, placebo-controlled trial of divalproex ER oral loading (begun at 15 mg/kg/d and titrated to a maximum of 30 mg/kg/d) in ambulatory BSD with hypomania/mild mania patients, operationally defined as a Young Mania Rating Scale (YMRS) score ≥‘ ‰10 but <‘ ‰21 at baseline and at 1 other study visit at least 3 days apart over the 2 weeks before baseline, was conducted. Patients were enrolled from October 2003 through November 2007.

Results: Sixty patients (n‘ ‰=‘ ‰30 in the divalproex ER group) had at least 1 postbaseline assessment. The divalproex ER group showed a significantly greater rate of reduction in mean total YMRS score than the placebo group (longitudinal analysis, P‘ ‰=‘ ‰.024). The divalproex ER group also showed more improvement in depressive symptoms the greater the severity of baseline depression (P‘ ‰=‘ ‰.11 for analysis of covariance treatment-by-baseline interaction). Baseline-to-endpoint change scores using last-observation-carried-forward showed that divalproex ER was associated with a marginally significant change in mean total YMRS score (P‘ ‰=‘ ‰.080). Comparable numbers of patients discontinued divalproex ER (n‘ ‰=‘ ‰17) and placebo (n‘ ‰=‘ ‰15), including those that discontinued use because of adverse events (n‘ ‰=‘ ‰4 and 3, respectively).

Conclusions: Divalproex ER begun at 15 mg/kg/d was superior to placebo in reducing hypomanic/mild manic symptoms in ambulatory BSD. It was associated with fairly good tolerability but a high discontinuation rate. Controlled trials of divalproex ER and other mood stabilizers in larger groups of ambulatory BSD patients with hypomanic/mild manic symptoms appear warranted.

Trial Registration: clinicaltrials.gov Identifier: NCT00278772

J Clin Psychiatry

Submitted: November 5, 2008; accepted January 9, 2009.

Online ahead of print: February 23, 2010 (doi:10.4088/JCP.08m04854yel).

Corresponding author: Susan L. McElroy, MD, 4075 Old Western Row Road, Mason, OH 45040 (susan.mcelroy@lindnercenter.org).

Volume: 71

Quick Links: Bipolar Disorder

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...